Title: Effectiveness of nirmatrelvir-ritonavir against hospital admission: a matched cohort study in a large US healthcare system

Authors: Joseph A. Lewnard, PhD[1,2,3,*]; Debbie Malden, DPhil[4]; Vennis Hong, MPH[4]; Laura Puzniak, PhD, MPH[5]; Jeniffer S. Kim, PhD[4]; Sally F. Shaw, DrPH[4]; Harpreet Takhar, MPH[4]; Luis Jodar, PhD[5]; John M. McLaughlin, PhD,[5]; Sara Y. Tartof, PhD, MPH[4,6,*]

Affiliations:
1. Division of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States
2. Division of Infectious Diseases & Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States
3. Center for Computational Biology, College of Engineering, University of California, Berkeley, Berkeley, California 94720, United States
4. Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California 91101, United States
5. Pfizer Inc, New York, New York.
6. Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California 91101, United States

* Addresses for correspondence:

Joseph A. Lewnard
2121 Berkeley Way
Berkeley, California 94720
jLewnard@berkeley.edu
510-664-4050

Sara Y. Tartof
100 South Los Robles
Pasadena, California 91101
Sara.Y.Tartof@kp.org
626-564-3001

ABSTRACT

Background: In the United States, oral nirmatrelvir-ritonavir (Paxlovid[TM]) is authorized for use among patients aged ≥12 years with mild-to-moderate SARS-CoV-2 infection who are at risk for progression to severe COVID-19, including hospitalization. However, effectiveness under real-world conditions has not been well established.

Methods: We undertook a matched, observational cohort study of non-hospitalized individuals with SARS-CoV-2 infection to compare outcomes between those who received or did not receive nirmatrelvir-ritonavir within the Kaiser Permanente Southern California healthcare system. Individuals were matched on testing date, age, sex, treatment/care setting, symptoms status (including presence or absence of acute COVID-19 symptoms at testing, and time from symptom onset to testing), history of vaccination and SARS-CoV-2 infection, Charlson comorbidity index, and prior-year healthcare utilization. Time to hospital admission was compared between matched COVID-19 cases who received or did not receive nirmatrelvir-ritonavir. Primary analyses evaluated treatment effectiveness against any hospital admission and acute respiratory infection (ARI)-associated hospital admission, with dispense occurring 0–5 days symptom onset. Secondary analyses evaluated effectiveness against the same endpoints for all treatment dispenses. We measured treatment effectiveness as (1–adjusted hazards ratio [aHR])×100%, estimating the aHR via Cox proportional hazards models accounting for match strata and additional patient characteristics.

Results: Analyses included 4,329 nirmatrelvir-ritonavir recipients and 20,980 matched non-recipients who were followed ≥30 days after a positive SARS-CoV-2 outpatient test. Overall, 23,603 (93.3%) and 19,564 (78.1%) of 25,039 participants had received ≥2 and ≥3 COVID-19 vaccine doses, respectively. A total of 23,858 (94.2% of 25,039) patients were symptomatic at the point of testing, with a 2.1 day mean time from symptom onset to testing. For patients dispensed nirmatrelvir-ritonavir 0–5 days after symptom onset, effectiveness in preventing all hospital admissions was 88.1% (95% confidence interval: 49.0–97.5%) over 15 days and 71.9% (25.3–90.0%) over 30 days, respectively. Effectiveness in preventing ARI-associated hospital admissions was 88.3% (12.9–98.8%) and 87.3% (18.3–98.5%) over 15 and 30 days, respectively. In expanded analyses that included patients receiving treatment at any point during their clinical course, effectiveness was 86.6% (54.9–96.3%) and 78.0% (46.2–91.4%) in preventing all hospital admissions over 15 and 30 days, respectively, and 93.7% (52.5–99.4%) and 92.8% (53.9–99.1%) in preventing ARI-associated hospital admissions over 15 and 30 days. Subgroup analyses identified similar effectiveness estimates among patients who had received ≥2 COVID-19 vaccine doses.

Implications: In a real-world setting with high levels of COVID-19 vaccine and booster uptake, receipt of nirmatrelvir-ritonavir 0–5 days after symptom onset was associated substantial reductions in risk of hospital admission among individuals testing positive for SARS-CoV-2 infection in outpatient settings.

Funding: US Centers for Disease Control and Prevention, US National Institutes of Health

INTRODUCTION

In conjunction with vaccination as a primary prevention strategy, therapeutic drugs to prevent severe outcomes of SARS-CoV-2 infection are of key importance to current efforts aimed at mitigating the burden of COVID-19. In early trials, neutralizing monoclonal antibody therapies[1–3] and remdesivir,[4] an antiviral agent repurposed for treatment of COVID-19 cases, showed success in preventing hospital admissions when administered early in patients' clinical course. However, the need to deliver these treatments by intravenous infusion has limited their utility for broad implementation in ambulatory care settings. In the randomized phase II/III EPIC-HR trial among high-risk, unvaccinated, and non-hospitalized adults,[5] oral nirmatrelvir-ritonavir (Paxlovid™, Pfizer, Inc.) was found to reduce the risk of COVID-19 related hospital admission by 89% over 28 days following treatment dispense. Based on this evidence, the US Food and Drug Administration issued Emergency Use Authorization for nirmatrelvir-ritonavir for adults and children aged ≥12 years weighing ≥40 kilograms who are at high risk for progression to severe COVID-19.

Amid the broad implementation of nirmatrelvir-ritonavir for COVID-19 cases diagnosed in ambulatory settings,[6] evidence is needed on treatment effectiveness under real-world conditions of use. In recent observational studies, nirmatrelvir-ritonavir was estimated to confer 21–79% reductions in risk of COVID-19 related hospital admission or other severe endpoints, with the strongest evidence of clinical benefit found among high-risk subgroups including older adult patients, obese patients, and patients not known to have immunity to SARS-CoV-2 from prior infection or vaccination.[7–12] However, these studies have lacked sufficient statistical power to demonstrate effectiveness in other subpopulations that are at relatively low risk of severe illness; have been undertaken in contexts where access to treatment is relatively limited; and have lacked data describing patients' clinical status, including time from symptom onset, which may inform clinical decision-making around prescribing nirmatrelvir-ritonavir.[13] While data from the United States have identified that COVID-19 related emergency department (ED) presentations and hospital admissions are infrequent among patients receiving nirmatrelvir-ritonavir in ambulatory care settings,[14,15] systematic assessments of effectiveness are lacking. We therefore aimed to measure the effectiveness of nirmatrelvir-ritonavir in preventing severe outcomes of SARS-CoV-2 infection among cases ascertained via outpatient testing within a large, integrated US healthcare system.

METHODS

Setting. Our study was conducted within Kaiser Permanente Southern California (KPSC), a comprehensive healthcare system providing integrated care across virtual, outpatient, emergency department (ED), and inpatient settings to 4.7 million members (~19% of the population of southern California). Members of KPSC are enrolled through employer-provided, pre-paid, and federally-sponsored insurance plans and represent the diverse socioeconomic characteristics and racial/ethnic backgrounds of the geographic areas served.[16,17] Electronic health records (EHRs) capture all within-network care delivery including diagnoses, pharmacy dispenses, laboratory tests and results, and vaccinations received. Care received out of network is captured through insurance claim reimbursements.

COVID-19 vaccinations received outside KPSC were captured through the California Immunization Registry, to which providers were required to report all COVID-19 vaccine administrations within 24 hours.[18] Patients were eligible for inclusion in the current study if they had a documented positive SARS-CoV-2 polymerase chain reaction (PCR) test result between 31 December, 2021 and 29 July, 2022. We included follow-up for clinical endpoints in this study occurring through 28 August, 2022.

Design, sample, and matching. We used a matched cohort framework to compare risk of hospitalization over a 30-day period following nirmatrelvir-ritonavir dispense for cases aged ≥12 years who tested positive for SARS-CoV-2 in any outpatient setting and over a corresponding 30-day period for matched non-recipients. Patients were considered to have received outpatient diagnoses if they had no interaction with healthcare services within 0-7 days before testing or if their interactions over this period occurred in ED, urgent care, physician office, or virtual settings. Patients were excluded if they had a positive SARS-CoV-2 test result ≤90 days prior to their index test date during the study period, were tested while hospitalized, or had any hospital admission 0-7 days before testing. To mitigate immortal time bias in a manner consistent with the design of the EPIC-HR trial,[5] we initiated follow-up from the date of dispense of nirmatrelvir-ritonavir for recipients, and from an equivalent number of days after testing for matched non-recipients; thus, analyses were restricted to recipients and matched non-recipients who had not experienced study endpoints through equivalent phases of their clinical course by the time of follow-up initiation, as detailed below.

For each recipient of nirmatrelvir-ritonavir, we selected up to 50 matched individuals testing positive for SARS-CoV-2 who i) did not receive nirmatrelvir-ritonavir and ii) did not experience any study endpoint over an interval equal in length to the index case's time from testing to treatment dispense. To ensure comparability of recipients' and non-recipients' clinical status and epidemiologic characteristics at the initiation of follow-up, matching criteria included time from symptom onset to testing (±1 day), or absence of symptoms at the point of testing, in addition to the following characteristics: calendar

week (or weekend) of SARS-CoV-2 test, age (±10 years), sex, prior-year healthcare utilization (≥1 inpatient admission, ≥1 ED presentation, and the total number of outpatient visits [0-4, 5-9, 10-14, 15-19, 20-29, or ≥30]), documented prior SARS-CoV-2 infection (yes/no), history of COVID-19 vaccination, Charlson comorbidity index (0, 1–2, 3–5, or ≥6), highest level of care received in association with the current positive SARS-CoV-2 test (ED, urgent care, office visit, telehealth, or no interaction with healthcare services within 0-7 days prior to testing). Prior COVID-19 vaccination was defined according to the number of doses received ≥14 days before testing, and receipt of the most recent dose within 90 days before testing. The date of SARS-CoV-2 symptom onset was defined as the earliest date of acute fever, cough, headache, fatigue, dyspnea, chills, sore throat, myalgia, anosmia, diarrhea, vomiting/nausea, or abdominal pain occurring within 14 days prior to the testing date. Symptoms were abstracted from structured questionnaires administered for each SARS-CoV-2 test order as well as from unstructured text fields within patient EHRs, as described previously.[19] Individuals treated with nirmatrelvir-ritonavir without eligible matches were excluded from analyses.

Endpoints and follow-up. Hospital admission after a positive outpatient test was the primary endpoint of interest; our analyses followed patients for admissions due to any cause and admissions with any acute respiratory infection (ARI) diagnosis (**Table S1**). To emulate clinical trial design and accommodate potential lag times between diagnosis and treatment dispense,[5] we initiated follow-up time from the date of treatment dispense for recipients of nirmatrelvir-ritonavir, who had not experienced study endpoints prior to treatment, and from an equivalent number of days after SARS-CoV-2 testing for individually matched non-recipients, who (like the recipients) had not experienced study endpoints from their date of testing to this index date of follow-up. We included follow-up through 15 and 30 days thereafter for all-cause hospital admissions and ARI-associated hospital admissions. We censored follow-up at the end of these 15- and 30-day monitoring periods, or at disenrollment from KPSC, whichever occurred earlier. For analyses of ARI-associated hospital admissions, we additionally censored follow-up at hospital admissions not associated with any ARI diagnosis.

Statistical analysis. We defined treatment effectiveness as $(1 - \text{adjusted hazards ratio [aHR]}) \times 100\%$, for the aHR comparing outcomes among recipients of nirmatrelvir-ritonavir to outcomes among matched non-recipients. We estimated the aHR using Cox proportional hazards regression models for each endpoint, defining regression strata for matched sets of participants who received and did not receive nirmatrelvir-ritonavir. Models additionally adjusted for demographic, medical, and socioeconomic characteristics not used in generating match sets, including patients' race/ethnicity (non-Hispanic White, non-Hispanic Asian, non-Hispanic Black, Pacific Islander, Hispanic, and other/unknown/multiple race), body mass index (BMI; underweight [<18.5], normal weight [18.5-24.9], overweight [25.0-29.9], obese [30-39.9], or morbidly obese [≥40.0]), cigarette smoking (currently, formerly or never smoking), census-tract neighborhood deprivation index (quintiles),[20] and receipt of other vaccines including 2021-22 season influenza vaccination, pneumococcal polysaccharide vaccine, and pneumococcal conjugate vaccine (**Table 1**). Models further included a continuous age covariate to account for any potential differences in risk across the span of ages included within each matched set.

Primary analyses were limited to patients who reported symptoms at the time of testing and whose index date for follow-up occurred within 0–5 days after symptom onset. Secondary analyses included symptomatic individuals whose index date for follow-up occurred within ≥6 days after symptom onset, and all individuals regardless of symptoms presence, absence, or timing in relation to follow-up initiation. To better understand the implications of matching individuals on clinical status at the point of testing—defined as presence or absence of symptoms and time from symptom onset to testing—we repeated analyses allowing looser matching with respect to these symptom-based characteristics. The first and second of these sensitivity analyses matched individuals according to presence of symptoms at time of testing, but considered non-recipients of treatment to be eligible for matching if their time from symptom onset to testing was within ±3 days or ±5 days from that of the index case. The third of these sensitivity analyses did not match individuals on presence of symptoms at the point of testing, or time from symptom onset to testing. We also conducted sensitivity analyses restricting the sample to patients who had received ≥2 doses of COVID-19 vaccine ≥14 days before testing.

Because smoking status, BMI, and census-tract neighborhood deprivation index measures may be missing within KSPC records,[21] we conducted multiple imputation to sample from the joint distribution of these variables with respect to all other observed characteristics of cases.[22] We repeated analyses across each of 10 independent pseudo-datasets completed via imputation of missing observations. For each imputed dataset, we assembled matched sets of recipients and non-recipients via a random sequence, thus further propagating variability resulting from match assignments. Reported results pool parameter estimates across analyses undertaken with each of the 10 pseudo-datasets according to Rubin's rules.[23]

Finally, because treatment effects identified under the Cox proportional hazards framework describe the effects of both preventing and delaying progression to each endpoint,[24] we repeated analyses estimating the adjusted risk ratio (aOR) of each outcome among recipients vs. matched non-recipients of nirmatrelvir-ritonavir. We fit conditional logistic regression models to estimate the aOR of each hospital admission endpoint over 15- and 30-day follow-up periods. Conditional logistic regression models included match strata as defined for the Cox proportional hazards models, and adjusted for all other measured exposures (as listed above and in **Table 1**) by covariate adjustment.

All analyses were performed using R software (version 4.2.1; R Foundation for Statistical Computing, Vienna, Austria). The study was approved by the KPSC Institutional Review Board, which granted a waiver of informed consent.

RESULTS

In total, 480,712 KPSC members received positive SARS-CoV-2 test results during the study period, including 473,414 (98.5% of 480,712) who were eligible for inclusion in analyses as having new-onset infections (without prior positive results within ≤90 days) diagnosed within outpatient settings (**Figure 1**). Within this population, 451,490 (95.4% of 473,414) cases were diagnosed by 29 July, 2022, among whom 10,442 (2.3% of 451,490) were dispensed nirmatrelvir-ritonavir by end of follow-up. Among those aged ≥50 and ≥65 years (for whom nirmatrelvir-ritonavir is recommended regardless of underlying comorbid conditions), 7,101/136,084 (5.2%) and 3,844/47,289 (8.1%) received nirmatrelvir-ritonavir, respectively. Recipients of nirmatrelvir-ritonavir were more likely to have had outpatient care interactions in association with SARS-CoV-2 testing (23.3% [2,437/10,442] of recipients vs. 18.5% [81,577/441,048] of non-recipients), had higher levels of healthcare utilization in the preceding year, had greater prevalence of comorbid conditions (56.0% [5,846/10,442] of recipients vs. 23.1% [101,781/441,048] of non-recipients having Charlson comorbidity scores ≥1), were more likely to have received vaccines against other respiratory pathogens (71.6% [7,480/10,442] of recipients vs. 45.5% [200,739/441,048] of non-recipients received 2021-22 seasonal influenza vaccine), and received greater numbers of COVID-19 vaccine doses (8.2% [867/10,442] of recipients vs. 27.1% [119,701/441,048] of non-recipients were unvaccinated against COVID-19; **Table S2**).

The proportion of all individuals testing positive for SARS-CoV-2 in outpatient settings who received treatment increased during the study period, from 0.014% during the week beginning 31 December, 2021 to 7.6% during the week beginning 29 July, 2022. Likewise, the risk profile of nirmatrelvir-ritonavir recipients declined over this period of rollout. From January to July 2022, the proportion of recipients with a Charlson comorbidity index ≥1 declined from 71.9% (39/139) to 56.5% (2,218/3,924), and the proportion who were unvaccinated declined from 18.0% (25/139) to 7.8% (308/3,924). Additionally, mean age of recipients declined from 60.9 years to 57.6 years (**Figure 2**). Median time from symptom onset to treatment dispense among recipients declined from 5 to 3 days, suggesting treatment may have been offered to an increasing proportion of cases at mild or moderate stages of illness; likewise, the proportion of recipients dispensed treatment before or within 1 day of symptom onset increased from 8.6% (12/139) to 19.4% (763/3,924; **Figure 3**).

We identified 20,980 matches for 4,329 recipients of nirmatrelvir-ritonavir, who collectively formed the analytic sample (**Table S3**). As compared to 6,113 recipients of nirmatrelvir-ritonavir without matches identified, recipients included in the analytic sample were younger, were less likely to have had healthcare interactions with healthcare services in association with their SARS-CoV-2 test (13.9% [603/4,329] of included recipients vs. 30.0% [1,834/6,113] of excluded recipients), had lower prevalence of comorbid conditions (39.2% [1,699/4,329] of included recipients vs. 67.8% [4,147/6,113] of excluded recipients having Charlson comorbidity scores ≥1), and were tested at shorter intervals following reported dates of symptom onset (mean 2.2 days among included recipients vs. 3.8 days among excluded recipients). Regarding patient characteristics not included in defining match assignments, patients' racial/ethnic backgrounds, histories of smoking, and neighborhood deprivation index values were similar between recipients and non-recipients of nirmatrelvir-ritonavir within the analytic sample (**Table 1**). While recipients were more likely to be obese or morbidly obese than non-recipients (51.9% [2,012/3,878] of recipients vs. 41.8% [6,819/16,318] of non-recipients, among those with BMI recorded), and were more likely to have received vaccines against other respiratory pathogens (68.8% [2,978/4,329] of recipients vs. 56.9% [11,945/20,980] of non-recipients received 2021-22 seasonal influenza vaccine), these differences were considerably less pronounced within the matched analytic sample than within the general study population (**Table S2**).

Throughout follow-up, rates of hospital admission and ARI-associated hospital admission were 3.7 and 2.2 admissions per 100,000 person-days among recipients of nirmatrelvir-ritonavir and 4.6 and 2.4 admissions per 100,000 person-days among non-recipients. For matched pairs followed beginning 0–5 days after treatment dispense (and over a corresponding observation period for non-recipients), discordant outcomes in which the recipient was hospitalized while observations for non-recipients were censored before any hospital admission occurred a median of 9 and 11 times during 15 and 30 days, respectively, across all analysis iterations (**Table 2**). In contrast, discordant outcomes in which the non-recipient was hospitalized while the recipient was censored occurred a median of 31 and 47 times. Adjusting for differences in characteristics of matched recipients and non-recipients that were not accounted for in generating match assignments, we estimated the effectiveness of nirmatrelvir-ritonavir, when administered 0–5 days after symptom onset, was 88.1% (95% confidence interval: 49.0–97.5%) and 71.9% (25.3–90.0%) in preventing hospital admissions due to all causes over 15 and 30 days, respectively.

Restricting the hospital admission endpoint to instances associated with ARI diagnoses, we observed a median of 7 matched pairs in which the recipient was hospitalized while the non-recipient was censored, and 19 and 21 matched pairs

in which the non-recipient was hospitalized and the recipient was censored over 15- and 30-day follow-up periods, respectively (**Table 2**). We estimated the effectiveness of nirmatrelvir-ritonavir, when administered 0-5 days after symptom onset, was 88.3% (12.9–98.8%) and 87.3% (18.3–98.5%) in preventing ARI-associated hospital admissions at 15 and 30 days, respectively.

Insufficient data were available to support regression analyses limited to matched pairs in which nirmatrelvir-ritonavir was dispensed to the index recipient ≥6 days after symptom onset. However, within this stratum, analyses of all endpoints and across both the 15- and 30-day observation windows identified a greater number of matched pairs in which non-recipients were hospitalized while recipients were censored, in comparison to the number of matched pairs in which recipients were hospitalized while non-recipients were censored (**Table 2**). For analyses not restricted to patients with symptoms or those treated within a specified time from symptom onset, we estimated the effectiveness of nirmatrelvir-ritonavir was 86.6% (54.9–96.3%) and 78.0% (46.2–91.4%) in preventing hospital admissions due to all causes over 15 and 30 days, respectively. Estimated effectiveness in preventing ARI-associated hospital admissions within this expanded sample was 93.7% (52.5–99.4%) and 92.8% (53.9–99.1%), respectively, over 15 and 30 days.

Analyses restricted to individuals who had received ≥2 COVID-19 vaccine doses yielded similar point estimates of treatment effectiveness for all endpoints, notwithstanding reduced statistical power within this lower-risk subgroup (**Table S4**). We estimated that nirmatrelvir-ritonavir, when administered 0–5 days after symptoms onset, prevented 85.2% (33.3–97.0%) and 66.1% (8.9–88.0%) of all-cause hospital admissions over 15 and 30 days, respectively, and 83.2% (–24.9–98.3%) and 82.3% (–10.3–97.7%) of ARI-associated hospital admissions over 15 and 30 days, within this stratum.

Analyses allowing for looser matches on time from symptom onset to testing (±3 day or ±5 day) for nirmatrelvir-ritonavir recipients and non-recipients yielded weaker estimates of treatment effectiveness against all endpoints. For all-cause hospital admissions, point estimates of treatment effectiveness were in the range of 69.4–71.0% and 61.8–65.7% over 15 days and 30 days, respectively, while for ARI-associated hospital admissions, point estimates of treatment effectiveness were in the range of 62.3–69.3% and 53.9–68.2% over 15 days and 30 days (**Table S5**, **Table S6**). For analyses which did not include matching on symptoms presence or absence at testing, or on time from symptom onset to testing, treatment effectiveness estimates against all-cause hospital admission were 46.8% (13.3–67.5%) and 44.5% (17.5–62.9%) over 15 and 30 days; for ARI-associated hospital admissions, estimated effectiveness was 45.9% (–2.2–71.1%) and 45.2% (1.4–70.0%) over 15 and 30 days (**Table S7**).

For all study endpoints and exposure definitions, further secondary analyses measuring treatment effectiveness from the aOR of each outcome among recipients vs. matched non-recipients of nirmatrelvir-ritonavir yielded absolute effectiveness estimates differing by ≤1.1 percentage points from those estimated via the aHR (**Table S8**).

DISCUSSION

In this matched cohort study conducted among a highly vaccinated population in a large US healthcare system, nirmatrelvir-ritonavir was highly effective at preventing hospitalization following a positive outpatient test for SARS-CoV-2 infection. When initiated within the first 5 days following COVID-19 symptom onset, nirmatrelvir-ritonavir prevented 88% of hospitalizations due to all causes and 88% of ARI-associated hospitalizations over the ensuing 15 days. Effectiveness was similar (point estimates: 87–94%) for nirmatrelvir-ritonavir courses initiated at any time, regardless of symptoms, although it should be noted that 94% of recipients of nirmatrelvir-ritonavir in our study were symptomatic at testing and few received treatment >5 days after symptom onset. Within our analysis, protection against hospitalization persisted over the longer 30-day observation period following treatment dispense. Point estimates of effectiveness against ARI-associated hospital admission through 30 days were in the range of 87–93%, while point estimates of effectiveness against all-cause hospital admission were in the range of 71–78%. This waning effect for prevention of all-cause hospitalizations likely signifies the accumulation of hospital admissions due to causes unrelated to COVID-19 over a longer, 30-day follow-up period; hospital admissions during the first 15 days of follow-up were more likely to be associated with ARI diagnoses.

Our estimates of effectiveness closely resemble efficacy estimates in the randomized EPIC-HR trial, which was conducted among non-hospitalized adults with mild to moderate COVID-19 at high risk of developing severe disease. Within the trial, patients who received nirmatrelvir-ritonavir within the first 5 days of symptom onset were 88% less likely to be hospitalized compared to those who received placebo over the ensuing 28 days.[5] Despite finding similar point estimates, our results add important context to those from the clinical trial. First, whereas the EPIC-HR trial was conducted during the Delta (B.1.617.2) wave, our study confirms high effectiveness of nirmatrelvir-ritonavir in a period when most treated cases were likely infected with BA.4/BA.5 Omicron lineages.[15] Second, the EPIC-HR trial included only individuals who had no history of confirmed SARS-CoV-2 infection and who had never received a COVID-19 vaccine. Our study, however, showed a significant further benefit of treatment for preventing hospitalization in a cohort where 94% of recipients had received ≥1

COVID-19 vaccine dose, and 77% had received ≥3 doses. High prevalence of prior infection was also expected among our sample at this phase of the pandemic, with at least 58% of the US population estimated to have been infected through the end of the BA.1 Omicron wave.[25] This background immunity was unlikely to be fully captured by individuals' documented history of infection in their EHR, as some prior infections may have gone untested or may have been ascertained by testing in the home or other settings.[21] Thus, although absolute risk of severe clinical outcomes was lower in our analytic sample than within the population of the EPIC-HR trial, our findings of 87–88% effectiveness broadly confirm the benefit of treatment under current real-world conditions of high COVID-19 vaccine uptake and SARS-CoV-2 seroprevalence.

Several studies have aimed to assess effectiveness of nirmatrelvir-ritonavir under real-world conditions of use in Israel, Hong Kong, and the United States, each yielding lower effectiveness estimates than those observed in the EPIC-HR trial.[7–12] Because the perceived risk for a patient to progress to severe disease endpoints likely factors into clinical decision-making around nirmatrelvir-ritonavir prescribing and patients' adherence to treatment, controlling for potential differences in clinical status among patients who receive or do not receive treatment is of key importance to causal inference. However, symptoms data were lacking in prior observational studies from all[7–11] or most[12] patients analyzed, hindering the possibility to control for differences in patients' clinical stage or disease severity potentially associated with treatment receipt. Our sensitivity analyses allowing for relaxed matches with respect to patients' symptomatic status identified progressively lower estimates of treatment effectiveness with looser matching on time from symptoms to testing, and without matching on presence or timing of symptoms. A related challenge arises in mitigating immortal time bias resulting from delays between testing and treatment initiation for recipients of nirmatrelvir-ritonavir.[26] Most prior studies[7–10,12] have defined treatment as a time-varying exposure to capture clinical endpoints occurring before treatment initiation as part of "unexposed" person-time at risk. However, this approach may nonetheless introduce bias if risk of severe outcomes differs during the days occurring between testing and treatment dispense versus days occurring at later stages of the clinical course, after individuals would be expected to receive treatment. Our strategy of matching treatment recipients and non-recipients on time from symptom onset to treatment, and to thereafter index follow-up for severe endpoints from the time of treatment dispense, aimed to emulate trial design and avoid capturing clinically-distinct risk periods within the exposed and unexposed arms. Last, while other studies have controlled for sociodemographic characteristics and comorbid conditions within their samples, healthcare utilization behaviors may also differ between individuals who receive and do not receive nirmatrelvir-ritonavir following a positive outpatient test. Such differences in healthcare utilization may affect whether individuals seek a prescription for nirmatrelvir-ritonavir, as well as their likelihood and timing of filling a prescription ordered by their healthcare provider. These circumstances support our inclusion of prior-year healthcare utilization, receipt of outpatient or virtual care in association with testing, and receipt of other (e.g. seasonal influenza) vaccination as matching or adjustment variables.

The distribution of demographic and clinical characteristics of patients receiving nirmatrelvir-ritonavir changed over the study period as access to treatment expanded in this study setting. The proportion of treatment dispenses occurring among vaccinated patients, patients of younger age, and patients without major medical comorbidities increased over the study period, while median time from symptom onset to treatment declined by two days between January and July, 2022. These factors may merit consideration when comparing results from our study to earlier studies conducted in settings where access to nirmatrelvir-ritonavir was relatively constrained, as reserving treatment for patients at the greatest risk of severe outcomes may confound effectiveness estimates.[6,27]

Our observational study has at least six limitations. First, we cannot rule out the possibility of differences in clinical and epidemiologic characteristics of COVID-19 cases who received or did not receive nirmatrelvir-ritonavir. However, access to data on timing of symptom onset, acuity of the setting where care was received (e.g., telehealth, physician office, urgent care, or ED), and healthcare utilization outside of the current COVID-19 episode offered opportunities to address confounding not available in prior observational studies. Second, while our ability to track healthcare utilization across virtual, outpatient, and inpatient settings as well as external insurance claim reimbursements is a strength of this study, capture of prior infections is likely imperfect, especially for infections presenting without symptoms or those ascertained by at-home testing. Prevalent naturally-acquired immunity, in addition to high levels of COVID-19 vaccination coverage in the KPSC population, may have contributed to lower risk of severe clinical endpoints within our sample. Third, we cannot verify whether patients who received nirmatrelvir-ritonavir adhered to treatment as recommended. However, treatment non-adherence would have biased effectiveness estimates towards the null, and this circumstance supports the interpretation of our findings as measuring intention-to-treat effects under real-world conditions of uptake and treatment adherence. Fourth, ARI diagnoses may provide an imperfect indication of the causal role of COVID-19 in hospital admissions. Regardless, our study identifies nirmatrelvir-ritonavir to be effective in preventing all-cause hospital admissions, in addition to those associated with ARI diagnoses. Fifth, because not all individuals who received nirmatrelvir-ritonavir were matched to non-recipient controls, the external generalizability of our findings needs to be confirmed in other study populations. By carefully matching recipients to non-recipients, we prioritized balancing exposure groups across known potential confounding factors to help mitigate bias driven by confounding by indication or differences

in health-seeking behavior. Lastly, patients who may have received treatment with other antivirals were not excluded from the current analysis. However, molnupiravir was the only other approved antiviral therapy for treatment of mild- to moderate COVID-19 in the outpatient setting during this study period. Because its use was reserved for patients with nirmatrelvir-ritonavir treatment contraindications, it was rarely prescribed and was unlikely to have affected the study findings.

In summary, when compared to matched non-recipients, recipients of nirmatrelvir-ritonavir were 87–88% less likely to have a COVID-19-related hospitalization following a positive outpatient SARS-CoV-2 test across all ages and in a population that was highly vaccinated. These findings confirm the added value of nirmatrelvir-ritonavir in preventing severe clinical outcomes, despite the potential risk of prolonged viral shedding after treatment,[28] in populations with high levels of immunity derived either from vaccination or prior natural infection.

REFERENCES

1. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. *NEJM* 2021; 384: 229–37.

2. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab. *NEJM* 2021; 385: 1941–50.

3. Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody combination and outcomes in outpatients with COVID-19. *NEJM* 2021; 385: e81.

4. Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe COVID-19 in outpatients. *NEJM* 2022; 386: 305–15.

5. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. *NEJM* 2022; 386: 1397–408.

6. Gold JAW. Dispensing of oral antiviral drugs for treatment of COVID-19 by zip code level social vulnerability — United States, December 23, 2021–May 21, 2022. *Morb Mortal Wkly Rep* 2022; 71. doi:10.15585/mmwr.mm7125e1.

7. Arbel R, Wolff Sagy Y, Hoshen M, et al. Nirmatrelvir use and severe COVID-19 outcomes during the Omicron Surge. *NEJM* 2022; NEJMoa2204919.

8. Dryden-Peterson S, Kim A, Kim AY, et al. Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system. *medRxiv* 2022; doi:10.1101/2022.06.14.22276393.

9. Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in reducing severe COVID-19 and mortality in high-risk patients. *Clin Infect Dis* 2022; ciac443.

10. Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir against mortality, hospitalization, and in-hospital outcomes among community-dwelling, ambulatory COVID-19 patients during the BA.2.2 wave in Hong Kong: an observational study. *medRxiv* 2022; doi:10.1101/2022.05.26.22275631.

11. Yip TCF, Lui GCY, Lai MSM, et al. Impact of the use of oral antiviral agents on the risk of hospitalization in community COVID-19 patients. *Clin Infecdt Dis* 2022; ciac687.

12. Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis 2022; doi:10.1016/S1473-3099(22)00507-2.

13. Heil EL, Kottilil S. The Goldilocks time for remdesivir — is any indication just right? *NEJM* 2022; 386: 385–7.

14. Malden DE, Hong V, Lewin BJ, et al. Hospitalization and emergency department encounters for COVID-19 after Paxlovid treatment — California, December 2021–May 2022. *Morb Mortal Wkly Rep* 2022; 71. doi:10.15585/mmwr.mm7125e2.

15. Lewnard JA, Hong V, Tartof SY. Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome. *medRxiv* 2022; doi:10.1101/2022.07.31.22278258.

16. Lewnard JA, Liu VX, Jackson ML, et al. Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study. *BMJ* 2020; 369: m1923.

17. Koebnick C, Langer-Gould AM, Gould MK, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. *Perm J* 2012; 16: 37–41.

18. Andrejko KL, Myers JF, Fukui N, et al. Real-world uptake of COVID-19 vaccination among individuals expressing vaccine hesitancy: a registry-linkage study. *medRxiv* 2022; doi:10.1101/2022.08.02.22278300.

19. Malden DE, Tartof SY, Ackerson BK, et al. Natural language processing for improved COVID-19 characterization: evidence from more than 350,000 patients in a large integrated health care system. *SSRN* 2022; doi:10.2139/ssrn.4075842.

20. Messer LC, Laraia BA, Kaufman JS, et al. The development of a standardized neighborhood deprivation index. *J Urban Health* 2006; 83: 1041–62.

21. Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California. *Nat Med* 2022; 28: 1933–43.

22. Honaker J, King G, Blackwell M. Amelia II: a program for missing data. *J Stat Softw* 2011; doi:10.18637/jss.v045.i07.

23. Rubin DB. Multiple imputation after 18+ years: *J Am Stat Assoc* 1996; 91, 473–89.

24. Stensrud MJ, Hernan MA. Why test for proportional hazards? *JAMA* 2020; 323: 1401–2.

25. Clarke KEN, Jones JM, Deng Y, et al. Seroprevalence of infection-induced SARS-CoV-2 antibodies — United States, September 2021–February 2022. *Morb Mortal Wkly Rep* 2022; 71. doi:10.15585/mmwr.mm7117e3.

26. Martinuka O, von Cube M, Wolkewitz M. Methodological evaluation of bias in observational coronavirus disease 2019 studies on drug effectiveness. *Clin Microbiol Infect* 2021; 27: 949–57.

27. Fiscella K, Sanders M, Yaeger J. Strategies to promote equity in COVID-19 antiviral treatment. *JAMA* 2022; 3: e220050.

28. Anderson AS, Caubel P, Rusnak JM. Nirmatrelvir–ritonavir and viral load rebound in COVID-19. *NEJM* 2022; 387: 1047–9.

ACKNOWLEDGMENTS

This study was funded by the US Centers for Disease Control & Prevention (grant 75D3-121C11520 to SYT) and the National Institute for Allergy and Infectious Diseases of the US National Institutes of Health (grant R01-AI4812701A1 to JAL).

DATA SHARING STATEMENT

Anonymized data that support the findings of this study may be made available from the investigative team in the following conditions: (1) agreement to collaborate with the study team on all publications, (2) provision of external funding for administrative and investigator time necessary for this collaboration, (3) demonstration that the external investigative team is qualified and has documented evidence of training for human subjects protections, and (4) agreement to abide by the terms outlined in data use agreements between institutions.

DISCLOSURES

JAL discloses receipt of grants and honoraria from Pfizer, Inc. separately from this study. SYT discloses receipt of grants from Pfizer, Inc. separately from this study. LP, LJ, and JMM are employees of Pfizer, Inc.

Table 1: Characteristics of the analytic sample.

Characteristic		Exposure, *n* (%)	
		Paxlovid received	Paxlovid not received
		N=4,329	*N*=20,980
Age			
	≤19 years	37 (0.9)	466 (2.2)
	20-29 years	207 (4.8)	1945 (9.3)
	30-39 years	615 (14.2)	4788 (22.8)
	40-49 years	961 (22.2)	6118 (29.2)
	50-59 years	1049 (24.2)	4648 (22.2)
	60-69 years	959 (22.2)	2288 (10.9)
	70-79 years	419 (9.7)	617 (2.9)
	≥80 years	82 (1.9)	110 (0.5)
Sex			
	Male	1791 (41.4)	9095 (43.4)
Time from symptoms onset to testing			
	Mean days (±standard deviation)	2.2 (±2.3)	2.1 (±1.7)
	No symptoms indicated at point of testing	265 (6.1)	1186 (5.7)
Highest-level care received[1]			
	Emergency department	43 (1.0)	83 (0.4)
	Urgent care	50 (1.0)	185 (0.4)
	Outpatient office visit	211 (4.9)	767 (3.7)
	Telehealth consultation	299 (6.9)	609 (2.9)
	No care appointment	3726 (86.1)	19336 (92.2)
Charlson comorbidity index			
	0	2630 (60.8)	17419 (83.0)
	1-2	1465 (33.8)	3268 (15.6)
	3-5	203 (4.7)	259 (1.2)
	≥6	31 (0.7)	34 (0.2)
Prior-year healthcare interactions			
	0-4 outpatient visits	816 (18.8)	7995 (38.1)
	5-9 outpatient visits	1249 (28.9)	7305 (34.8)
	10-14 outpatient visits	825 (19.1)	2727 (13.0)
	15-19 outpatient visits	498 (11.5)	1137 (5.4)
	20-29 outpatient visits	541 (12.5)	1088 (5.2)
	≥30 outpatient visits	400 (9.2)	728 (3.5)
	Any ED presentation	1022 (23.6)	2215 (10.6)
	Any inpatient admission	47 (1.1)	61 (0.3)
Prior SARS-CoV-2 infection			
	Any documented infection	9 (0.2)	15 (0.1)
Prior COVID-19 vaccination			
	0 doses received	266 (6.1)	1356 (6.5)
	1 dose received (>90 days before testing)	26 (0.6)	58 (0.3)
	1 dose received (≤90 days before testing)	0	0
	2 doses received (>90 days before testing)	688 (15.9)	3331 (15.9)
	2 doses received (≤90 days before testing)	5 (0.1)	15 (0.1)
	3 doses received (>90 days before testing)	2838 (65.6)	15270 (72.8)
	3 doses received (≤90 days before testing)	57 (1.3)	215 (1.0)
	4 doses received (>90 days before testing)	84 (1.9)	107 (0.5)
	4 doses received (≤90 days before testing)	365 (8.4)	628 (3.0)
Race[2]			
	White, non-Hispanic	1016 (23.5)	4216 (20.1)
	Black, non-Hispanic	346 (8.0)	1293 (6.2)
	Hispanic	1857 (42.9)	9472 (45.1)
	Asian	765 (17.7)	3559 (17.0)
	Pacific Islander	45 (1.0)	242 (1.2)
	Other/unknown/mixed race	300 (6.9)	2198 (10.5)
Body mass index[2,3]			
	Underweight (<18.5)	23 (0.6)	180 (1.1)
	Normal weight (18.5-24.9)	689 (17.8)	3748 (23.0)
	Overweight (25.0-29.9)	1154 (29.8)	5571 (34.1)
	Obese (30-39.9)	1536 (39.6)	5566 (34.1)
	Morbidly obese (≥40.0)	476 (12.3)	1253 (7.7)
Cigarette smoking[2,3]			
	Current smoker	140 (3.6)	685 (4.2)
	Former smoker	794 (20.6)	2794 (17.0)
	Never smoked	2923 (75.8)	12999 (78.9)
Neighborhood deprivation index[2,3]			
	First quintile (least deprived)	700 (16.4)	3000 (14.6)
	Second quintile	958 (22.5)	4620 (22.4)
	Third quintile	1104 (25.9)	5203 (25.2)
	Fourth quintile	937 (22.0)	4689 (22.7)
	Fifth quintile (most deprived)	568 (13.3)	3106 (15.1)
Receipt of other respiratory vaccines[2]			
	2021-22 seasonal influenza vaccine	2978 (68.8)	11945 (56.9)

Pneumococcal conjugate vaccine	861 (19.9)	1522 (7.3)
Pneumococcal polysaccharide vaccine	1976 (45.6)	4547 (21.7)

Data on exposure prevalence among treatment recipients and non-recipients include all eligible cases who were assigned matches across all 10 analysis iterations. Within each iteration, treatment recipients were assigned up to 10 non-recipients as matches; recipients were not excluded if fewer than 10 eligible matches were available. Characteristics used for matching may thus be imbalanced between treatment recipients and non-recipients in this tabulation.

[1]Highest-level outpatient care received 0-7 days before testing; levels are ranked as emergency department (highest acuity), urgent care, physician office visit, and telehealth consultation (lowest acuity).

[2]Variables not included in matching assignments; these variables were controlled for in regression models via covariate adjustment.

[3]Variables imputed due to missingness (19.7% of smoking observations, 20.2% of body mass index observations, and 0.8% of neighborhood deprivation index observations among included participants). Percentages are computed among individuals with non-missing observations.

Table 2: Effectiveness of oral nirmatrelvir-ritonavir for prevention of hospital admission.

Endpoint	Timing of dispense	Discordant pairs, median (range) across match iterations[1]		Effectiveness (95% CI), %
		Outcome observed for recipient, non-recipient censored	Outcome observed for non-recipient, recipient censored	
Hospital admission over 15 days after treatment—any				
	0-5 days after symptoms onset	9 (7, 11)	31 (30, 31)	88.1 (49.0, 97.5)
	≥6 days after symptoms onset	4 (4, 6)	9 (9, 10)	– –
	At any time, regardless of symptoms	13 (11, 17)	43 (42, 44)	86.6 (54.9, 96.3)
Hospital admission over 30 days after treatment—any				
	0-5 days after symptoms onset	11 (9, 14)	47 (46, 47)	71.9 (25.3, 90.0)
	≥6 days after symptoms onset	4 (4, 6)	12 (12, 13)	– –
	At any time, regardless of symptoms	15 (14, 20)	63 (62, 64)	78.0 (46.2, 91.4)
Hospital admission over 15 days after treatment—acute respiratory infection diagnosis[2]				
	0-5 days after symptoms onset	7 (5, 9)	19 (18, 19)	88.3 (12.9, 98.8)
	≥6 days after symptoms onset	4 (4, 6)	6 (6, 7)	– –
	At any time, regardless of symptoms	11 (9, 15)	27 (26, 28)	93.7 (52.5, 99.4)
Hospital admission over 30 days after treatment—acute respiratory infection diagnosis[2]				
	0-5 days after symptoms onset	7 (5, 9)	21 (20, 21)	87.3 (18.3, 98.5)
	≥6 days after symptoms onset	4 (4, 6)	7 (7, 8)	– –
	At any time, regardless of symptoms	11 (9, 15)	30 (29, 31)	92.8 (53.9, 99.1)

Treatment effectiveness is measured as $(1 - \text{adjusted hazard ratio}) \times 100\%$, comparing outcomes among individuals who received treatment to those who did not. Time at risk is measured from treatment dispense date, for treatment recipients, and from an equivalent number of days following testing for non-recipients. Recipients are matched to up to 50 non-recipients on the basis of: age (±10 years); sex; time from symptoms onset to testing (±1 day) or absence of symptoms at the point of testing; highest-level outpatient care received within 0-7 days before testing (emergency department, urgent care, physician office visit, and telehealth consultation); Charlson comorbidity index (0, 1-2, 3-5, and ≥6); prior-year healthcare interactions (including 0-4, 5-9, 10-14, 15-19, 20-29, ≥30 outpatient visits, any emergency department presentation, and any inpatient admission); prior documented SARS-CoV-2 infection; and prior COVID-19 vaccination, defined by number of doses received ≥14 days prior testing and receipt of the last dose within 14-90 days before testing. Further variables listed in **Table 1**, but not used to define match sets, are controlled for via covariate adjustment.

[1]Data indicate the median and range of the number of discordant pairs across iterations in which match lists were assembled via a random sequence.

[2]Diagnosis codes used to define ARI-associated hospital admissions are listed in **Table S1**.

Figure 1: Study flowchart. We indicate numbers of patients excluded due to each criterion, and the numbers retained in analyses.

Figure 2: Changes over time in the population receiving treatment. Indexing cases by week of their index positive test, panels in the top row illustrate (**A**) total new-onset positive SARS-CoV-2 cases identified via polymerase chain reaction testing in outpatient settings; (**B**) the number of outpatient-identified cases subsequently admitted to hospital; (**C**) the number of outpatient-identified cases receiving oral nirmatrelvir-ritonavir; and (**D**) the proportion of outpatient-identified cases receiving oral nirmatrelvir-ritonavir. Panels in the bottom row disaggregate the proportion of outpatient-identified cases receiving oral nirmatrelvir-ritonavir according to (**E**) age group; (**F**) Charlson comorbidity index values; (**G**) number of vaccine doses received; and (**H**) setting in which care was received in association with the positive SARS-CoV-2 test.

Figure 3: Times from symptom onset to testing and treatment dispense. Panels illustrate (**A**) time from symptoms onset to SARS-CoV-2 testing among all positive cases identified at KSPC over the study period (including a subpanel plotting the distribution of times from testing to symptoms onset, for cases with reported symptoms onset after testing); (**B**) time from symptoms onset to oral nirmatrelvir-ritonavir dispense, for patients who received treatment (including a subpanel illustrating time from testing to treatment dispense); and (**C**) times from symptoms onset to treatment dispense, disaggregated by week of testing, for patients who received treatment. Shaded areas in panel **C** illustrate the probability distribution of treatment times, and are plotted proportionally to the number of patients treated (square root-transformed) in order to aid visualization of changes over time in volume.

Supporting information

Effectiveness of nirmatrelvir-ritonavir against hospital admission: a matched cohort study in a large US healthcare system

Joseph A. Lewnard, PhD[1,2,3,*]; Debbie Malden, DPhil[4]; Vennis Hong, MPH[4]; Laura Puzniak, PhD, MPH[5]; Jeniffer S. Kim, PhD[4]; Sally F. Shaw, DrPH[4]; Harpreet Takhar, MPH[4]; Luis Jodar, PhD[5]; John M. McLaughlin, PhD,[5]; Sara Y. Tartof, PhD, MPH[4,6,*]

1. Division of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States
2. Division of Infectious Diseases & Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States
3. Center for Computational Biology, College of Engineering, University of California, Berkeley, Berkeley, California 94720, United States
4. Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California 91101, United States
5. Pfizer Inc, New York, New York.
6. Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California 91101, United States

*   Addresses for correspondence:

Joseph A. Lewnard
2121 Berkeley Way
Berkeley, California 94720
jLewnard@berkeley.edu
510-664-4050

Sara Y. Tartof
100 South Los Robles
Pasadena, California 91101
Sara.Y.Tartof@kp.org
626-564-3001

Contents of this supplement

Table S1: Diagnosis codes used to identify acute respiratory infection-associated hospital admissions.

Code	Diagnosis
A48.1	Legionnaire's disease
B34.2	Coronavirus infection (unspecified)
B44.0	Invasive pulmonary aspergillosis
B97.29	Other coronavirus as the cause of diseases classified elsewhere
J00	Acute nasopharyngitis (common cold)
J01.00	Acute maxillary sinusitis, unspecified
J01.10	Acute frontal sinusitis, unspecified
J01.20	Acute ethmoidal sinusitis, unspecified
J01.30	Acute sphenoidal sinusitis, unspecified
J01.40	Acute pansinusitis, unspecified
J01.80	Other acute sinusitis
J01.90	Acute sinusitis, unspecified
J02.0	Streptococcal pharyngitis
J02.8	Acute pharyngitis due to other specified organisms
J02.9	Acute pharyngitis, unspecified
J03.00	Acute streptococcal tonsillitis, unspecified
J03.90	Acute tonsillitis, unspecified
J04.0	Acute laryngitis
J04.10	Acute tracheitis without obstruction
J05.0	Acute obstructive laryngitis (croup)
J05.10	Acute epiglottitis without obstruction
J06.0	Acute laryngopharyngitis
J06.9	Acute upper respiratory infection, unspecified
J09.X1	Influenza due to identified novel influenza A virus with pneumonia
J09.X2	Influenza due to identified novel influenza A virus with other respiratory manifestations
J10.00	Influenza due to other identified influenza virus with unspecified type of pneumonia
J10.01	Influenza due to other identified influenza virus with same other identified influenza virus pneumonia
J10.08	Influenza due to other identified influenza virus with other pneumonia
J10.1	Influenza due to other identified influenza virus with other respiratory manifestations
J10.2	Influenza due to other identified influenza virus with gastrointestinal manifestations
J11.00	Influenza due to unidentified influenza virus with unspecified type of pneumonia
J11.08	Influenza due to unidentified influenza virus with specified pneumonia
J11.1	Influenza due to unidentified influenza virus with other respiratory manifestations
J12.1	Respiratory syncytial virus pneumonia
J12.2	Parainfluenza virus pneumonia
J12.3	Human metapneumovirus pneumonia
J12.81	Pneumonia due to SARS-associated coronavirus
J12.82	Pneumonia due to coronavirus disease 2019
J12.89	Other viral pneumonia
J12.9	Viral pneumonia, unspecified
J13	Pneumonia due to *Streptococcus pneumoniae*
J14	Pneumonia due to *Haemophilus influenzae*
J15.0	Pneumonia due to *Klebsiella pneumoniae*
J15.1	Pneumonia due to *Pseudomonas*
J15.20	Pneumonia due to *Staphylococcus*, unspecified
J15.211	Pneumonia due to methicillin susceptible *Staphylococcus aureus*
J15.212	Pneumonia due to methicillin resistant *Staphylococcus aureus*
J15.4	Pneumonia due to other *Streptococci*
J15.5	Pneumonia due to *Escherichia coli*
J15.6	Pneumonia due to other aerobic gram-negative bacteria
J15.7	Pneumonia due to *Mycoplasma pneumoniae*
J15.8	Pneumonia due to other specified bacteria
J15.9	Unspecified bacterial pneumonia
J16.8	Pneumonia due to other specified infectious organisms
J18.0	Bronchopneumonia, unspecified organism
J18.1	Lobar pneumonia, unspecified organism
J18.8	Other pneumonia, unspecified organism
J18.9	Pneumonia, unspecified organism
J20.2	Acute bronchitis due to *Streptococcus*
J20.5	Acute bronchitis due to respiratory syncytial virus
J20.6	Acute bronchitis due to rhinovirus
J20.8	Acute bronchitis due to other specified organisms
J20.9	Acute bronchitis, unspecified
J22	Unspecified acute lower respiratory infection
J39.0	Retropharyngeal and parapharyngeal abscess
J39.1	Other abscess of pharynx

J39.2	Other diseases of pharynx
J39.8	Other specified diseases of upper respiratory tract
J80	Acute respiratory distress syndrome
J96.00	Acute respiratory failure, unspecified with hypoxia or hypercapnia
J96.01	Acute respiratory failure with hypoxia
J96.02	Acute respiratory failure with hypercapnia
J96.10	Chronic respiratory failure, unspecified with hypoxia or hypercapnia
J96.11	Chronic respiratory failure with hypoxia
J96.12	Chronic respiratory failure with hypercapnia
J96.20	Acute and chronic respiratory failure, unspecified with hypoxia or hypercapnia
J96.21	Acute and chronic respiratory failure with hypoxia
J96.22	Acute and chronic respiratory failure with hypercapnia
J96.90	Respiratory failure, unspecified with hypoxia or hypercapnia
J96.91	Respiratory failure with hypoxia
J96.92	Respiratory failure with hypercapnia
M35.81	Multisystem inflammatory syndrome
M35.89	Other specified systemic involvement of connective tissue
R05.1	Acute cough
R05.3	Chronic cough
R05.8	Other specified cough
R05.9	Cough, unspecified
R09.2	Respiratory arrest
R50.9	Fever, unspecified
U07.1	COVID-19

Table S2: Characteristics of all cases diagnosed as outpatients within Kaiser Permanente Southern California during the study period.

Characteristic		Exposure, *n* (%)	
		Paxlovid received	Paxlovid not received
		N=10,442	*N*=441,048
Age			
	≤19 years	105 (1.0)	93,404 (21.2)
	20-29 years	445 (4.3)	60,564 (13.7)
	30-39 years	1,109 (10.6)	83,960 (19.0)
	40-49 years	1,682 (16.1)	74,136 (16.8)
	50-59 years	2,132 (20.4)	62,035 (14.1)
	60-69 years	2,416 (23.1)	40144 (9.1)
	70-79 years	1,763 (16.9)	19,170 (4.3)
	≥80 years	790 (7.6)	7,635 (1.7)
Sex			
	Male	6,022 (57.7)	243,417 (55.2)
Time from symptoms onset to testing			
	Mean days (±standard deviation)	3.1 (±3.3)	3.9 (±3.5)
	No symptoms indicated at point of testing	844 (8.1)	99,866 (22.6)
Highest-level care received[1]			
	Emergency department	160 (1.5)	4,187 (0.9)
	Urgent care	247 (1.5)	8,281 (0.9)
	Outpatient office visit	875 (8.4)	38,577 (8.7)
	Telehealth consultation	1,155 (11.1)	30,532 (6.9)
	No care appointment	8,005 (76.7)	359,471 (81.5)
Charlson comorbidity index			
	0	4,596 (44.0)	339,267 (76.9)
	1-2	4,031 (38.6)	78,819 (17.9)
	3-5	1,381 (13.2)	16,182 (3.7)
	≥6	434 (4.2)	6,780 (1.5)
Prior-year healthcare interactions			
	0-4 outpatient visits	1,254 (12.0)	130,811 (29.7)
	5-9 outpatient visits	2,171 (20.8)	111,304 (25.2)
	10-14 outpatient visits	1,911 (18.3)	65,546 (14.9)
	15-19 outpatient visits	1,434 (13.7)	40,650 (9.2)
	20-29 outpatient visits	1,721 (16.5)	44,345 (10.1)
	≥30 outpatient visits	1,951 (18.7)	48,392 (11.0)
	Any ED presentation	4,066 (38.9)	92,692 (21.0)
	Any inpatient admission	696 (6.7)	32,250 (7.3)
Prior SARS-CoV-2 infection			
	Any documented infection	235 (2.3)	8,753 (2.0)
Prior COVID-19 vaccination			
	0 doses received	867 (8.3)	119,701 (27.1)
	1 dose received (>90 days before testing)	214 (2.0)	14,387 (3.3)
	1 dose received (≤90 days before testing)	8 (0.1)	5,308 (1.2)
	2 doses received (>90 days before testing)	1,754 (16.8)	150,905 (34.2)
	2 doses received (≤90 days before testing)	27 (0.3)	15,733 (3.6)
	3 doses received (>90 days before testing)	5,383 (51.6)	77,211 (17.5)
	3 doses received (≤90 days before testing)	216 (2.1)	47,416 (10.8)
	4 doses received (>90 days before testing	543 (5.2)	2,503 (0.6)
	4 doses received (≤90 days before testing)	1,430 (13.7)	7,884 (1.8)
Race[2]			
	White, non-Hispanic	2,967 (28.4)	97,243 (22.0)
	Black, non-Hispanic	977 (9.4)	35,015 (7.9)
	Hispanic	4,306 (41.2)	217,665 (49.4)
	Asian	1,596 (15.3)	47,925 (10.9)
	Pacific Islander	90 (0.9)	3,624 (0.8)
	Other/unknown/mixed race	506 (4.8)	39,576 (9.0)
Body mass index[2,3]			
	Underweight (<18.5)	90 (0.9)	34,442 (9.4)
	Normal weight (18.5-24.9)	1,994 (20.4)	89,029 (24.2)
	Overweight (25.0-29.9)	3,623 (30.7)	111,638 (28.6)
	Obese (30-39.9)	3,006 (37.0)	104,962 (30.4)
	Morbidly obese (≥40.0)	1,074 (11.0)	27,440 (7.5)
Cigarette smoking[2,3]			
	Current smoker	379 (3.9)	14,879 (4.3)
	Former smoker	2,319 (23.9)	52,968 (15.2)
	Never smoked	6,999 (72.2)	280,404 (80.5)
Neighborhood deprivation index[2,3]			

		Treatment recipients	Non-recipients
	First quintile (least deprived)	1,691 (16.3)	57,009 (13.0)
	Second quintile	2,380 (23.0)	92,202 (21.1)
	Third quintile	2,600 (25.1)	108,763 (24.8)
	Fourth quintile	2,233 (21.9)	105,134 (24.0)
	Fifth quintile (most deprived)	1,414 (13.7)	74,778 (17.1)
Receipt of other respiratory vaccines[2]			
	2021-22 seasonal influenza vaccine	7,480 (71.6)	200,739 (45.5)
	Pneumococcal conjugate vaccine	3,588 (34.4)	106,420 (24.1)
	Pneumococcal polysaccharide vaccine	6,123 (58.6)	97,729 (22.2)

Data on exposure prevalence among treatment recipients and non-recipients include all eligible cases who were assigned matches across all 10 analysis iterations. Within each iteration, treatment recipients were assigned up to 10 non-recipients as matches; recipients were not excluded if fewer than 10 eligible matches were available. Characteristics used for matching may thus be imbalanced between treatment recipients and non-recipients in this tabulation.

[1]Highest-level outpatient care received 0-7 days before testing; levels are ranked as emergency department (highest acuity), urgent care, physician office visit, and telehealth consultation (lowest acuity).

[2]Variables not included in matching assignments; these variables were controlled for in regression models via covariate adjustment.

[3]Variables imputed due to missingness. Percentages are computed among individuals with non-missing observations.

Table S3: Characteristics of treated cases included or not included in the analytic sample.

Characteristic		Exposure, *n* (%)	
		Included in analysis (matched)	Excluded from analysis (unmatched)
		N=4,329	*N*=6,113
Age			
	≤19 years	37 (0.9)	68 (1.1)
	20-29 years	207 (4.8)	238 (3.9)
	30-39 years	615 (14.2)	494 (8.1)
	40-49 years	961 (22.2)	721 (11.8)
	50-59 years	1049 (24.2)	1,083 (17.7)
	60-69 years	959 (22.2)	1,457 (23.8)
	70-79 years	419 (9.7)	1,344 (22.0)
	≥80 years	82 (1.9)	708 (11.6)
Sex			
	Male	1791 (41.4)	2,629 (43.0)
Time from symptoms onset to testing			
	Mean days (±standard deviation)	2.2 (±2.3)	3.8 (±3.7)
	No symptoms indicated at point of testing	265 (6.1)	579 (9.5)
Highest-level care received[1]			
	Emergency department	43 (1.0)	117 (1.9)
	Urgent care	50 (1.0)	197 (1.9)
	Outpatient office visit	211 (4.9)	664 (10.9)
	Telehealth consultation	299 (6.9)	856 (14.0)
	No care appointment	3726 (86.1)	4,279 (70.0)
Charlson comorbidity index			
	0	2630 (60.8)	1,966 (32.2)
	1-2	1465 (33.8)	2,566 (42.0)
	3-5	203 (4.7)	1,178 (19.3)
	≥6	31 (0.7)	403 (6.6)
Prior-year healthcare interactions			
	0-4 outpatient visits	816 (18.8)	438 (7.2)
	5-9 outpatient visits	1249 (28.9)	922 (15.1)
	10-14 outpatient visits	825 (19.1)	1,086 (17.8)
	15-19 outpatient visits	498 (11.5)	936 (15.3)
	20-29 outpatient visits	541 (12.5)	1,180 (19.3)
	≥30 outpatient visits	400 (9.2)	1,551 (25.4)
	Any ED presentation	1022 (23.6)	3,044 (49.8)
	Any inpatient admission	47 (1.1)	649 (10.6)
Prior SARS-CoV-2 infection			
	Any documented infection	9 (0.2)	226 (3.7)
Prior COVID-19 vaccination			
	0 doses received	266 (6.1)	601 (9.8)
	1 dose received (>90 days before testing)	26 (0.6)	188 (3.1)
	1 dose received (≤90 days before testing)	0	8 (0.1)
	2 doses received (>90 days before testing)	688 (15.9)	1,066 (17.4)
	2 doses received (≤90 days before testing)	5 (0.1)	22 (0.4)
	3 doses received (>90 days before testing)	2838 (65.6)	2,545 (41.6)
	3 doses received (≤90 days before testing)	57 (1.3)	159 (2.6)
	4 doses received (>90 days before testing	84 (1.9)	459 (7.5)
	4 doses received (≤90 days before testing)	365 (8.4)	1,065 (17.4)
Race[2]			
	White, non-Hispanic	1016 (23.5)	1,951 (31.9)
	Black, non-Hispanic	346 (8.0)	631 (10.3)
	Hispanic	1857 (42.9)	2,449 (40.1)
	Asian	765 (17.7)	831 (13.6)
	Pacific Islander	45 (1.0)	45 (0.7)
	Other/unknown/mixed race	300 (6.9)	206 (3.4)
Body mass index[2,3]			
	Underweight (<18.5)	23 (0.6)	67 (1.1)
	Normal weight (18.5-24.9)	689 (17.8)	1,305 (22.1)
	Overweight (25.0-29.9)	1154 (29.8)	1,852 (31.3)
	Obese (30-39.9)	1536 (39.6)	2,087 (35.3)
	Morbidly obese (≥40.0)	476 (12.3)	598 (10.1)
Cigarette smoking[2,3]			
	Current smoker	140 (3.6)	239 (4.1)
	Former smoker	794 (20.6)	1,525 (26.1)
	Never smoked	2923 (75.8)	4,076 (69.8)
Neighborhood deprivation index[2,3]			

	First quintile (least deprived)	700 (16.4)	991 (16.3)
	Second quintile	958 (22.5)	1,422 (23.4)
	Third quintile	1104 (25.9)	1,496 (24.6)
	Fourth quintile	937 (22.0)	1,326 (21.8)
	Fifth quintile (most deprived)	568 (13.3)	846 (13.9)
Receipt of other respiratory vaccines[2]			
	2021-22 seasonal influenza vaccine	2978 (68.8)	4,502 (73.6)
	Pneumococcal conjugate vaccine	861 (19.9)	2,727 (44.6)
	Pneumococcal polysaccharide vaccine	1976 (45.6)	4,147 (67.8)

Data on exposure prevalence among treatment recipients and non-recipients include all eligible cases who were assigned matches across all 10 analysis iterations. Within each iteration, treatment recipients were assigned up to 10 non-recipients as matches; recipients were not excluded if fewer than 10 eligible matches were available. Characteristics used for matching may thus be imbalanced between treatment recipients and non-recipients in this tabulation.

[1]Highest-level outpatient care received 0-7 days before testing; levels are ranked as emergency department (highest acuity), urgent care, physician office visit, and telehealth consultation (lowest acuity).

[2]Variables not included in matching assignments; these variables were controlled for in regression models via covariate adjustment.

[3]Variables imputed due to missingness. Percentages are computed among individuals with non-missing observations.

Table S4: Effectiveness of oral nirmatrelvir-ritonavir for prevention of hospital admission in sensitivity analyses restricted to recipients of ≥2 COVID-19 vaccine doses.

Endpoint	Timing of dispense	Discordant pairs, median (range) across match iterations[1]		Effectiveness (95% CI), %
		Outcome observed for recipient, non-recipient censored	Outcome observed for non-recipient, recipient censored	
Hospital admission over 15 days after treatment—any				
	0-5 days after symptoms onset	9 (7, 11)	25 (25, 25)	85.2 (33.3, 97.0)
	≥6 days after symptoms onset	0 (0, 2)	9 (9, 9)	– –
	At any time, regardless of symptoms	9 (7, 13)	36 (36, 36)	85.2 (46.9, 96.2)
Hospital admission over 30 days after treatment—any				
	0-5 days after symptoms onset	11 (9, 13)	41 (41, 41)	66.1 (8.9, 88.0)
	≥6 days after symptoms onset	0 (0, 2)	12 (12, 12)	– –
	At any time, regardless of symptoms	11 (9, 15)	56 (56, 56)	77.0 (41.8, 91.3)
Hospital admission over 15 days after treatment—acute respiratory infection diagnosis[2]				
	0-5 days after symptoms onset	7 (5, 9)	15 (15, 15)	83.2 (–24.9, 98.3)
	≥6 days after symptoms onset	0 (0, 2)	6 (6, 6)	– –
	At any time, regardless of symptoms	7 (5, 11)	23 (23, 23)	90.2 (28.6, 98.9)
Hospital admission over 30 days after treatment—acute respiratory infection diagnosis[2]				
	0-5 days after symptoms onset	7 (5, 9)	17 (17, 17)	82.3 (–10.3, 97.7)
	≥6 days after symptoms onset	0 (0, 2)	7 (7, 7)	– –
	At any time, regardless of symptoms	7 (5, 11)	26 (26, 26)	89.3 (33.0, 98.6)

Treatment effectiveness is measured as $(1 - \text{adjusted hazard ratio}) \times 100\%$, comparing outcomes among individuals who received treatment to those who did not. Time at risk is measured from treatment dispense date, for treatment recipients, and from an equivalent number of days following testing for non-recipients. Recipients are matched to up to 50 non-recipients on the basis of: age (±10 years); sex; time from symptoms onset to testing (±1 day) or absence of symptoms at the point of testing; highest-level outpatient care received within 0-7 days before testing (emergency department, urgent care, physician office visit, and telehealth consultation); Charlson comorbidity index (0, 1-2, 3-5, and ≥6); prior-year healthcare interactions (including 0-4, 5-9, 10-14, 15-19, 20-29, ≥30 outpatient visits, any emergency department presentation, and any inpatient admission); prior documented SARS-CoV-2 infection; and prior COVID-19 vaccination, defined by number of doses received ≥14 days prior testing and receipt of the last dose within 14-90 days before testing. Further variables listed in **Table 1**, but not used to define match sets, are controlled for via covariate adjustment.

[1]Data indicate the median and range of the number of discordant pairs across iterations in which match lists were assembled via a random sequence.

[2]Diagnosis codes used to define ARI-associated hospital admissions are listed in **Table S1**.

Table S5: Effectiveness of oral nirmatrelvir-ritonavir for prevention of hospital admission in sensitivity analyses matching individuals by time from symptoms onset to testing, by ±3 days.

Endpoint	Timing of dispense	Discordant pairs, median (range) across match iterations[1]		Effectiveness (95% CI), %
		Outcome observed for recipient, non-recipient censored	Outcome observed for non-recipient, recipient censored	
Hospital admission over 15 days after treatment—any				
	0-5 days after symptoms onset	12 (11, 16)	40 (39, 41)	71.0 (20.1, 90.0)
	≥6 days after symptoms onset	6 (6, 8)	11 (11, 12)	– –
	At any time, regardless of symptoms	20 (17, 22)	61 (60, 62)	69.6 (30.8, 86.9)
Hospital admission over 30 days after treatment—any				
	0-5 days after symptoms onset	16 (15, 21)	63 (62, 64)	61.8 (16.1, 83.4)
	≥6 days after symptoms onset	7 (7, 9)	15 (15, 16)	– –
	At any time, regardless of symptoms	26 (23, 29)	91 (89, 92)	62.8 (29.7, 80.7)
Hospital admission over 15 days after treatment—acute respiratory infection diagnosis[2]				
	0-5 days after symptoms onset	8 (7, 12)	25 (24, 26)	69.3 (—14.7, 92.1)
	≥6 days after symptoms onset	6 (6, 8)	7 (7, 8)	– –
	At any time, regardless of symptoms	16 (13, 18)	38 (37, 39)	62.3 (–0.4, 86.2)
Hospital admission over 30 days after treatment—acute respiratory infection diagnosis[2]				
	0-5 days after symptoms onset	9 (8, 13)	27 (26, 28)	68.2 (–12.5, 91.3)
	≥6 days after symptoms onset	7 (7, 9)	8 (8, 9)	– –
	At any time, regardless of symptoms	18 (15, 20)	42 (41, 43)	53.9 (–8.4, 81.0)

Treatment effectiveness is measured as $(1 - \text{adjusted hazard ratio}) \times 100\%$, comparing outcomes among individuals who received treatment to those who did not. Time at risk is measured from treatment dispense date, for treatment recipients, and from an equivalent number of days following testing for non-recipients. Recipients are matched to up to 50 non-recipients on the basis of: age (±10 years); sex; time from symptoms onset to testing (±3 days) or absence of symptoms at the point of testing; highest-level outpatient care received within 0-7 days before testing (emergency department, urgent care, physician office visit, and telehealth consultation); Charlson comorbidity index (0, 1-2, 3-5, and ≥6); prior-year healthcare interactions (including 0-4, 5-9, 10-14, 15-19, 20-29, ≥30 outpatient visits, any emergency department presentation, and any inpatient admission); prior documented SARS-CoV-2 infection; and prior COVID-19 vaccination, defined by number of doses received ≥14 days prior testing and receipt of the last dose within 14-90 days before testing. Further variables listed in **Table 1**, but not used to define match sets, are controlled for via covariate adjustment.

[1]Data indicate the median and range of the number of discordant pairs across iterations in which match lists were assembled via a random sequence.

[2]Diagnosis codes used to define ARI-associated hospital admissions are listed in **Table S1**.

Table S6: Effectiveness of oral nirmatrelvir-ritonavir for prevention of hospital admission in sensitivity analyses matching individuals by time from symptoms onset to testing, by ±5 days.

Endpoint	Timing of dispense	Discordant pairs, median (range) across match iterations[1]		Effectiveness (95% CI), %
		Outcome observed for recipient, non-recipient censored	Outcome observed for non-recipient, recipient censored	
Hospital admission over 15 days after treatment—any				
	0-5 days after symptoms onset	14 (12, 17)	44 (43, 45)	70.2 (19.3, 89.7)
	≥6 days after symptoms onset	7 (6, 9)	11 (10, 12)	– –
	At any time, regardless of symptoms	25 (20, 29)	76 (74, 77)	69.4 (35.4, 85.9)
Hospital admission over 30 days after treatment—any				
	0-5 days after symptoms onset	18 (16, 22)	71 (70, 72)	65.7 (25.0, 85.2)
	≥6 days after symptoms onset	8 (7, 10)	17 (16, 18)	– –
	At any time, regardless of symptoms	34 (29, 28)	113 (111, 114)	62.3 (32.2, 79.4)
Hospital admission over 15 days after treatment—acute respiratory infection diagnosis[2]				
	0-5 days after symptoms onset	10 (8, 13)	27 (26, 28)	64.2 (–24.2, 90.3)
	≥6 days after symptoms onset	6 (5, 8)	7 (7, 8)	– –
	At any time, regardless of symptoms	20 (15, 24)	46 (45, 47)	62.7 (5.6, 85.9)
Hospital admission over 30 days after treatment—acute respiratory infection diagnosis[2]				
	0-5 days after symptoms onset	11 (9, 14)	30 (29, 31)	62.0 (–19.4, 88.6)
	≥6 days after symptoms onset	7 (6, 9)	8 (8, 9)	– –
	At any time, regardless of symptoms	23 (18, 27)	51 (50, 52)	55.1 (–1.8, 81.1)

Treatment effectiveness is measured as $(1 - \text{adjusted hazard ratio}) \times 100\%$, comparing outcomes among individuals who received treatment to those who did not. Time at risk is measured from treatment dispense date, for treatment recipients, and from an equivalent number of days following testing for non-recipients. Recipients are matched to up to 50 non-recipients on the basis of: age (±10 years); sex; time from symptoms onset to testing (±5 days) or absence of symptoms at the point of testing; highest-level outpatient care received within 0-7 days before testing (emergency department, urgent care, physician office visit, and telehealth consultation); Charlson comorbidity index (0, 1-2, 3-5, and ≥6); prior-year healthcare interactions (including 0-4, 5-9, 10-14, 15-19, 20-29, ≥30 outpatient visits, any emergency department presentation, and any inpatient admission); prior documented SARS-CoV-2 infection; and prior COVID-19 vaccination, defined by number of doses received ≥14 days prior testing and receipt of the last dose within 14-90 days before testing. Further variables listed in **Table 1**, but not used to define match sets, are controlled for via covariate adjustment.

[1]Data indicate the median and range of the number of discordant pairs across iterations in which match lists were assembled via a random sequence.

[2]Diagnosis codes used to define ARI-associated hospital admissions are listed in **Table S1**.

Table S7: Effectiveness of oral nirmatrelvir-ritonavir for prevention of hospital admission in sensitivity analyses not addressing occurring or timing of symptoms.

Endpoint	Discordant pairs, median (range) across match iterations[1]		Effectiveness (95% CI), %
	Outcome observed for recipient, non-recipient censored	Outcome observed for non-recipient, recipient censored	
Hospital admission over 15 days after treatment—any	71 (66, 84)	154 (148, 156)	46.8 (13.3, 67.5)
Hospital admission over 30 days after treatment—any	105 (100, 120)	230 (226, 233)	44.5 (17.5, 62.9)
Hospital admission over 15 days after treatment—acute respiratory infection diagnosis[2]	50 (46, 62)	92 (88, 93)	45.9 (–2.2, 71.7)
Hospital admission over 30 days after treatment—acute respiratory infection diagnosis[2]	59 (54, 74)	105 (101, 106)	45.2 (1.4, 70.0)

Treatment effectiveness is measured as $(1 - \text{adjusted hazard ratio}) \times 100\%$, comparing outcomes among individuals who received treatment to those who did not. Time at risk is measured from treatment dispense date, for treatment recipients, and from an equivalent number of days following testing for non-recipients. Recipients are matched to up to 50 non-recipients on the basis of: age (±10 years); sex; highest-level outpatient care received within 0-7 days before testing (emergency department, urgent care, physician office visit, and telehealth consultation); Charlson comorbidity index (0, 1-2, 3-5, and ≥6); prior-year healthcare interactions (including 0-4, 5-9, 10-14, 15-19, 20-29, ≥30 outpatient visits, any emergency department presentation, and any inpatient admission); prior documented SARS-CoV-2 infection; and prior COVID-19 vaccination, defined by number of doses received ≥14 days prior testing and receipt of the last dose within 14-90 days before testing. Further variables listed in **Table 1**, but not used to define match sets, are controlled for via covariate adjustment.
[1]Data indicate the median and range of the number of discordant pairs across iterations in which match lists were assembled via a random sequence.
[2]Diagnosis codes used to define ARI-associated hospital admissions are listed in **Table S1**.

Table S8: Effectiveness of oral nirmatrelvir-ritonavir for prevention of hospital admission, as measured by the matched odds ratio.

Endpoint	Timing of dispense	Effectiveness (95% CI), %
Hospital admission over 15 days after treatment—any		
	0-5 days after symptoms onset	87.5 (47.7, 97.3)
	≥6 days after symptoms onset	– –
	At any time, regardless of symptoms	87.7 (57.4, 96.8)
Hospital admission over 30 days after treatment—any		
	0-5 days after symptoms onset	71.2 (23.9, 89.8)
	≥6 days after symptoms onset	– –
	At any time, regardless of symptoms	78.2 (46.7, 91.5)
Hospital admission over 15 days after treatment—acute respiratory infection diagnosis[1]		
	0-5 days after symptoms onset	88.3 (13.0, 98.8)
	≥6 days after symptoms onset	– –
	At any time, regardless of symptoms	93.7 (52.4, 99.4)
Hospital admission over 30 days after treatment—acute respiratory infection diagnosis[1]		
	0-5 days after symptoms onset	87.3 (18.3, 98.5)
	≥6 days after symptoms onset	– –
	At any time, regardless of symptoms	92.8 (53.7, 99.1)

Treatment effectiveness is measured as $(1 - \text{adjusted odds ratio}) \times 100\%$, comparing outcomes among individuals who received treatment to those who did not. Recipients are matched to up to 50 non-recipients on the basis of: age (±10 years); sex; time from symptoms onset to testing (±1 day) or absence of symptoms at the point of testing; highest-level outpatient care received within 0-7 days before testing (emergency department, urgent care, physician office visit, and telehealth consultation); Charlson comorbidity index (0, 1-2, 3-5, and ≥6); prior-year healthcare interactions (including 0-4, 5-9, 10-14, 15-19, 20-29, ≥30 outpatient visits, any emergency department presentation, and any inpatient admission); prior documented SARS-CoV-2 infection; and prior COVID-19 vaccination, defined by number of doses received ≥14 days prior testing and receipt of the last dose within 14-90 days before testing. Further variables listed in **Table 1**, but not used to define match sets, are controlled for via covariate adjustment. Counts of discordant pairs are as presented in **Table 2**.
[1]Diagnosis codes used to define ARI-associated hospital admissions are listed in **Table S1**.